Peptide Comparison
Thymulin Analog (PAT)vsThymosin Beta-4
Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
Thymulin Analog (PAT)
1 mcg–50 mcg mcg
Thymosin Beta-4
2–5 mg
Frequency
Thymulin Analog (PAT)
Once daily
Thymosin Beta-4
Twice weekly
Administration
Thymulin Analog (PAT)
Intraperitoneal injection
Thymosin Beta-4
Subcutaneous injection
Cycle Length
Thymulin Analog (PAT)
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset Speed
Thymulin Analog (PAT)
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
Thymulin Analog (PAT)
Strong human trials (Phase 3 or FDA approved)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Pain Relief
Anti-Inflammatory
Neuroprotection
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
Thymulin Analog (PAT)
Molecular Formula
C37H62N12O15
Molecular Weight
858.9 Da
Half-Life
Effects peak at 1-2 hours; diminish by 3-4 hours post-single dose
Bioavailability
Effective via intraperitoneal and intracerebroventricular routes in preclinical models
CAS Number
Not assigned
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Applications
Best
suited for
Thymulin Analog (PAT)
Neuropathic pain research
Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory therapy development
Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Novel analgesic mechanism investigation
Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated pain pathway studies
Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
Thymulin Analog (PAT)
Common
- Injection Site Reaction
- Transient Immune Modulation
- Mild Sedation
- Short Duration of Action
Uncommon
- Potential Immune Suppression
- CNS Effects with Central Administration
Serious
- Unintended Immune Stimulation
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
Thymulin Analog (PAT)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.
Contraindications
- xNot approved for human use
- xPotential immune modulation concerns with chronic use
- xUnknown drug-drug interactions
- xPregnancy and lactation (insufficient safety data)
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose Thymulin Analog (PAT) if...
- Neuropathic pain research
- Anti-inflammatory therapy development
- Novel analgesic mechanism investigation
- Cytokine-mediated pain pathway studies
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation